バイオシミラー市場：製品、適応症、製造別-2025-2030年の世界予測

バイオシミラー市場は、2023年に407億米ドルと評価され、2024年には499億1,000万米ドルに達すると予測され、CAGR 23.31％で成長し、2030年には1,764億8,000万米ドルに達すると予測されています。

バイオシミラーは、すでに認可されている基準製品と類似性の高い生物学的製剤であり、高価な生物学的製剤に代わる費用対効果の高い代替品を提供する可能性があるため、医薬品業界の重要なセグメントとなっています。バイオシミラーの必要性は、増大する医療費とオリジナルの生物学的製剤の特許切れから生じ、がん、糖尿病、自己免疫疾患などの慢性疾患の治療において、手頃な価格の治療法への需要を牽引しています。その用途は腫瘍学、免疫学、内分泌学など様々な治療分野に及び、エンドユーザーの範囲は病院、診療所、研究機関にまで広がっています。市場成長は、慢性疾患の罹患率の上昇、規制当局の支援、ヘルスケアプロバイダーによるバイオシミラーの受け入れ拡大といった要因に大きく影響されます。さらに、新興市場や製造プロセスにおける技術的進歩は大きなビジネスチャンスとなります。バイオシミラー医薬品の普及と市場拡大のために、企業はヘルスケアプロバイダーとの戦略的提携や積極的なマーケティング戦略に注力すべきです。しかし、厳しい規制要件、知的財産の複雑さ、基準生物製剤との類似性を立証するための大規模な臨床試験の必要性などの課題も残っています。もう一つの限界は、先発品の生物製剤と比較して有効性や安全性に関する懸念が残るため、バイオシミラーの処方がためらわれることです。このようなハードルがあるにもかかわらず、この分野には、特にバイオシミラー開発プロセスの改善、ファーマコビジランス・システムの強化、サプライチェーンの効率最適化など、イノベーションのための豊富な道が残されています。企業は、互換性のあるバイオシミラー製剤の改良に重点を置いた調査に投資すべきであり、これによって薬局レベルでの自動的な代替が可能となり、市場浸透率が高まる。バイオシミラー市場の特徴は、特許切れと研究開発への高額投資による激しい競争であり、生物学的製剤に対する世界の需要の急増に対応するためには、継続的なイノベーションと適応性のあるマーケティング戦略が必要であることを示唆しています。

市場力学：急速に進化するバイオシミラー市場の主要市場インサイトを公開

バイオシミラー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 製薬業界へのヘルスケア支出の増加
  • オリジナルの生物製剤よりも低コストのバイオシミラー医薬品の需要の増加
• 市場抑制要因
  • バイオシミラーの処方に対する医師の消極性
• 市場機会
  • バイオシミラー製造プロセスの改善
  • バイオシミラーの開発に対する政府の支援策
• 市場の課題
  • 厳しい規制要件と法律

ポーターの5つの力：バイオシミラー市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、バイオシミラー市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：バイオシミラー市場における外部からの影響の把握

外部マクロ環境要因は、バイオシミラー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析バイオシミラー市場における競合情勢の把握

バイオシミラー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスバイオシミラー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、バイオシミラー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨バイオシミラー市場における成功への道筋を描く

バイオシミラー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬業界へのヘルスケア費支出の増加
    • オリジナルの生物学的製剤よりも低コストのバイオシミラー医薬品の需要増加
  • 抑制要因
    • 医師の処方への消極的態度バイオシミラー
  • 機会
    • バイオシミラー製造プロセスの改善
    • バイオシミラーの開発を支援する政府の取り組み
  • 課題
    • 厳格な規制要件と法律
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 バイオシミラー市場：製品別

• 組み換え糖化タンパク質
  • エリスロポエチン
  • フォリトロピン
  • モノクローナル抗体
    • アダリムマブ
    • インフリキシマブ
    • リツキシマブ
• 組み換え非糖化タンパク質
  • 顆粒球コロニー刺激因子
  • インスリン
  • インターフェロン
    • インターフェロンアルファ
    • インターフェロンベータ
  • 組み換えヒト成長ホルモン
• 組み換えペプチド
  • カルシトニン
  • グルカゴン

第7章 バイオシミラー市場適応症別

• 自己免疫疾患
• 血液疾患
• 慢性疾患
• 成長ホルモン欠乏症
• 感染症
• 腫瘍学

第8章 バイオシミラー市場製造業

• 契約製造
• 社内製造

第9章 南北アメリカのバイオシミラー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のバイオシミラー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのバイオシミラー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Alvotech
• Amgen Inc.
• Apotex Inc.
• Biocon Limited
• BioFactura, Inc.
• Biogen Inc.
• Boehringer Ingelheim International GmbH.
• Catalent, Inc
• Celltrion Healthcare Co.,Ltd.
• Coherus BioSciences
• Dr. Reddy's Laboratories Limited
• Eden Biologics, Inc.
• F. Hoffmann-La Roche AG
• Fresenius Kabi
• Innovent Biologics, Inc.
• Intas Pharmaceuticals Ltd.
• Kashiv BioSciences, LLC.
• Merck & Co., Inc.
• NeuClone
• Nippon Kayaku Co., Ltd.
• Novartis AG
• Panacea Biotec Limited
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sanofi S.A.
• Shanghai Henlius Biotech, Inc.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. BIOSIMILARS MARKET RESEARCH PROCESS
• FIGURE 2. BIOSIMILARS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOSIMILARS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOSIMILARS MARKET DYNAMICS
• TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 65. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 67. CANADA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 68. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 69. CANADA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 70. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 71. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 107. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 109. CHINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 110. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 111. CHINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 112. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 113. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 115. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 117. INDIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 118. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 119. INDIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 120. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 121. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 127. INDONESIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 134. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 135. JAPAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 142. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 143. MALAYSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 144. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 147. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 150. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 151. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 152. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 153. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 155. SINGAPORE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 158. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 159. SINGAPORE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 160. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 161. SINGAPORE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 171. TAIWAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 174. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 175. TAIWAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 176. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 177. TAIWAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 179. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 182. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 183. THAILAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 184. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 185. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 187. VIETNAM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 190. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 191. VIETNAM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 192. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 193. VIETNAM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 204. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 207. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 208. DENMARK BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 209. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 210. DENMARK BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 212. EGYPT BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 215. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 216. EGYPT BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 217. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 218. EGYPT BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 220. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 223. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 224. FINLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 225. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 226. FINLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 228. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 231. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 232. FRANCE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 233. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 234. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 236. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 239. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 240. GERMANY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 241. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 242. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 244. ISRAEL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 247. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 248. ISRAEL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 249. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 250. ISRAEL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 252. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 253. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 254. ITALY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 255. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 256. ITALY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 257. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 258. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 259. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 260. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 263. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 264. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 265. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 266. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 268. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 271. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 272. NIGERIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 273. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 274. NIGERIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 276. NORWAY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 279. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 280. NORWAY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 281. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 282. NORWAY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 284. POLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 285. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 286. POLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 287. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 288. POLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 289. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 290. POLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 291. POLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 292. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 293. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 294. QATAR BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 295. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 296. QATAR BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 297. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 298. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 299. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 300. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 303. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 304. RUSSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 305. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 306. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 308. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 310. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 311. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 312. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 314. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 316. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 318. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 319. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 320. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 321. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 322. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 324. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 325. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 326. SPAIN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 327. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 328. SPAIN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 329. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 330. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 331. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 332. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 333. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 334. SWEDEN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 335. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 336. SWEDEN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 337. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 338. SWEDEN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 339. SWEDEN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 340. SWITZERLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 341. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 342. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 343. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 344. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 345. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
• TABLE 346. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 347. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 348. TURKEY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 349. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 350. TURKEY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 351. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 352. TURKEY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
• TABLE 353. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)

TABLE 354

The Biosimilars Market was valued at USD 40.70 billion in 2023, expected to reach USD 49.91 billion in 2024, and is projected to grow at a CAGR of 23.31%, to USD 176.48 billion by 2030.

Biosimilars, biologic medical products highly similar to already authorized reference products, represent a key segment within the pharmaceutical industry due to their potential to offer cost-effective alternatives to expensive biologics. The necessity for biosimilars arises from increasing healthcare costs and patent expirations of original biologics, driving demand for affordable therapies in treating chronic diseases like cancer, diabetes, and autoimmune disorders. Their applications span across various therapeutic areas, including oncology, immunology, and endocrinology, with end-user scope extending to hospitals, clinics, and research institutes. Market growth is heavily influenced by factors such as rising incidences of chronic diseases, regulatory support, and healthcare providers' growing acceptance of biosimilars. Moreover, emerging markets and technological advancements in manufacturing processes present substantial opportunities. Businesses should focus on strategic collaborations with healthcare providers and aggressive marketing strategies to enhance biosimilar adoption and expand market reach. However, challenges persist, including stringent regulatory requirements, intellectual property complexities, and the need for extensive clinical trials to establish similarity to reference biologics. Another limitation is the hesitancy in prescribing biosimilars due to lingering concerns regarding efficacy and safety compared to original biologics. Despite these hurdles, the sector holds rich avenues for innovation, particularly in improving biosimilar development processes, enhancing pharmacovigilance systems, and optimizing supply chain efficiencies. Companies should invest in research focused on improving interchangeable biosimilar formulations, which can lead to automatic substitution at the pharmacy level, thereby increasing market penetration. The biosimilars market is characterized by intense competition driven by patent expirations and high research and development investments, suggesting that staying ahead necessitates continuous innovation and adaptive marketing strategies to capitalize on burgeoning global demand for biologic treatments.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biosimilars Market

The Biosimilars Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising healthcare expenditure into the pharmaceutical industry
  • Increasing demand for lower cost biosimilars drugs than original biologics
• Market Restraints
  • Reluctance of physicians to prescribe biosimilars
• Market Opportunities
  • Improvements in biosimilar production processes
  • Supportive government initiative to develop biosimilars
• Market Challenges
  • Stringent regulatory requirements and laws

Porter's Five Forces: A Strategic Tool for Navigating the Biosimilars Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biosimilars Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biosimilars Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biosimilars Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biosimilars Market

A detailed market share analysis in the Biosimilars Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biosimilars Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biosimilars Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biosimilars Market

A strategic analysis of the Biosimilars Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Alvotech, Amgen Inc., Apotex Inc., Biocon Limited, BioFactura, Inc., Biogen Inc., Boehringer Ingelheim International GmbH., Catalent, Inc, Celltrion Healthcare Co.,Ltd., Coherus BioSciences, Dr. Reddy's Laboratories Limited, Eden Biologics, Inc., F. Hoffmann-La Roche AG, Fresenius Kabi, Innovent Biologics, Inc., Intas Pharmaceuticals Ltd., Kashiv BioSciences, LLC., Merck & Co., Inc., NeuClone, Nippon Kayaku Co., Ltd., Novartis AG, Panacea Biotec Limited, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins is further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Monoclonal Antibodies is further studied across Adalimumab, Infliximab, and Rituximab. The Recombinant Non-Glycosylated Proteins is further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Interferons is further studied across Interferon-Alpha and Interferon-Beta. The Recombinant Peptides is further studied across Calcitonin and Glucagon.
• Based on Indication, market is studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.
• Based on Manufacturing, market is studied across Contract Manufacturing and In-House Manufacturing.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising healthcare expenditure into the pharmaceutical industry
    • 5.1.1.2. Increasing demand for lower cost biosimilars drugs than original biologics
  • 5.1.2. Restraints
    • 5.1.2.1. Reluctance of physicians to prescribe biosimilars
  • 5.1.3. Opportunities
    • 5.1.3.1. Improvements in biosimilar production processes
    • 5.1.3.2. Supportive government initiative to develop biosimilars
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements and laws
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biosimilars Market, by Product

• 6.1. Introduction
• 6.2. Recombinant Glycosylated Proteins
  • 6.2.1. Erythropoietin
  • 6.2.2. Follitropin
  • 6.2.3. Monoclonal Antibodies
    • 6.2.3.1. Adalimumab
    • 6.2.3.2. Infliximab
    • 6.2.3.3. Rituximab
• 6.3. Recombinant Non-Glycosylated Proteins
  • 6.3.1. Granulocyte Colony-Stimulating Factor
  • 6.3.2. Insulin
  • 6.3.3. Interferons
    • 6.3.3.1. Interferon-Alpha
    • 6.3.3.2. Interferon-Beta
  • 6.3.4. Recombinant Human Growth Hormone
• 6.4. Recombinant Peptides
  • 6.4.1. Calcitonin
  • 6.4.2. Glucagon

7. Biosimilars Market, by Indication

• 7.1. Introduction
• 7.2. Autoimmune Diseases
• 7.3. Blood Disorders
• 7.4. Chronic Diseases
• 7.5. Growth Hormone Deficiency
• 7.6. Infectious Diseases
• 7.7. Oncology

8. Biosimilars Market, by Manufacturing

• 8.1. Introduction
• 8.2. Contract Manufacturing
• 8.3. In-House Manufacturing

9. Americas Biosimilars Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Biosimilars Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Biosimilars Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alvotech
• 2. Amgen Inc.
• 3. Apotex Inc.
• 4. Biocon Limited
• 5. BioFactura, Inc.
• 6. Biogen Inc.
• 7. Boehringer Ingelheim International GmbH.
• 8. Catalent, Inc
• 9. Celltrion Healthcare Co.,Ltd.
• 10. Coherus BioSciences
• 11. Dr. Reddy's Laboratories Limited
• 12. Eden Biologics, Inc.
• 13. F. Hoffmann-La Roche AG
• 14. Fresenius Kabi
• 15. Innovent Biologics, Inc.
• 16. Intas Pharmaceuticals Ltd.
• 17. Kashiv BioSciences, LLC.
• 18. Merck & Co., Inc.
• 19. NeuClone
• 20. Nippon Kayaku Co., Ltd.
• 21. Novartis AG
• 22. Panacea Biotec Limited
• 23. Pfizer Inc.
• 24. Samsung Bioepis Co., Ltd.
• 25. Sanofi S.A.
• 26. Shanghai Henlius Biotech, Inc.
• 27. Teva Pharmaceutical Industries Ltd.
• 28. Thermo Fisher Scientific, Inc.